Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IgG-like bispecific antibodies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: AbCellera

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition August 20, 2020

            Details:

            Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Antisense oligonucleotide therapy

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Evotec

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 05, 2020

            Details:

            Partnership creates an opportunity for biotech and pharmaceutical companies to enter the growing field of antisense therapeutics by partnering with Evotec and Secarna and to gain access to the companies' co-owned pipeline through a variety of individual deal structures.

            Seattle Children’s Research Institute

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Engineered Regulatory T cell therapy

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Gentbio

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement August 05, 2020

            Details:

            Under the terms of the licensing agreements, Seattle Children’s, BRI and MIGAL will exclusively licenseunique technologies to GentiBio that overcome many of the current limitations of Tregs therapeutics,including rarity and plasticity of endogenous Tregs populations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hypoimmunogenic cells

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 29, 2020

            Details:

            First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.